Sagimet Biosciences Plunges 11.73% Amid Acne Treatment Updates

On June 13, 2025, Sagimet Biosciences experienced a significant drop of 11.73% in pre-market trading, marking a notable decline in its stock performance.

Sagimet Biosciences recently announced that it will host a virtual Key Opinion Leader (KOL) event titled "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Results." This event is expected to provide insights into the company's progress in developing new treatments for acne, which could potentially impact investor sentiment and stock performance.

Additionally, Jones Trading has lifted their price target on shares of Sagimet Biosciences from $15.00 to $27.00 and given the company a "buy" rating. This positive outlook from a reputable trading firm could influence investor confidence and future stock movements.